
{
  "Company Overview": {
    "Name": "NGL Fine Chem Ltd",
    "Sector": "Pharmaceuticals",
    "Industry": "Pharmaceuticals - Indian - Bulk Drugs",
    "Business Description": "Manufactures human and veterinary bulk drugs, intermediates, and formulations. Primarily deals in animal healthcare products such as antiprotozoal, anthelmintics, and growth promoters.",
    "Market Position": "Part of BSE SmallCap, BSE Allcap, BSE Healthcare.  Veterinary APIs account for 89% of revenues, followed by Veterinary Formulations (5%), Human APIs (3%), and Intermediates (3%).  The company has 26 APIs (24 Veterinary APIs, 2 Human APIs), 4 Intermediates and 10 finished dosage forms."
  },
  "Financial Metrics": {
    "Market Cap": "₹ 1,261 Cr.",
    "Current Price": "₹ 2,040",
    "High / Low": "₹ 2,824 / ₹ 1,702",
    "Stock P/E": "33.5",
    "Book Value": "₹ 452",
    "Dividend Yield": "0.09 %",
    "ROCE": "18.9 %",
    "ROE": "15.8 %",
    "Face Value": "₹ 5.00"
  },
  "Performance Trends": {
    "Quarterly Results": {
      "Sales": [78, 81, 78, 64, 65, 70, 74, 69, 79, 85, 96, 88, 91], 
      "Expenses": [62, 69, 68, 63, 60, 62, 62, 62, 66, 74, 83, 82, 81],
      "Operating Profit": [17, 12, 10, 0, 5, 7, 12, 8, 13, 11, 13, 6, 11],
      "OPM %": ["21%", "15%", "13%", "0%", "7%", "11%", "16%", "11%", "17%", "13%", "13%", "7%", "12%"],
      "Other Income": [5, 4, 2, 3, 4, 3, 1, 4, 4, 4, 4, 6, 5],
      "Interest": [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0],
      "Depreciation": [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2],
      "Profit before tax": [19, 14, 10, 1, 7, 8, 11, 9, 15, 13, 14, 10, 13],
      "Tax %": ["26%", "23%", "22%", "24%", "26%", "25%", "23%", "15%", "24%", "30%", "24%", "22%", "25%"],
      "Net Profit": [14, 11, 8, 1, 5, 6, 9, 8, 11, 9, 11, 8, 10],
      "EPS in Rs": [22.97, 17.56, 12.72, 0.83, 8.03, 9.86, 13.81, 12.64, 17.76, 14.41, 17.56, 12.67, 16.25]
    },
    "Annual Results": {
      "Sales": [56, 79, 88, 96, 100, 114, 153, 152, 258, 319, 275, 329, 360],
      "Expenses": [48, 68, 73, 74, 74, 92, 121, 129, 181, 253, 246, 284, 319],
      "Operating Profit": [8, 11, 15, 22, 25, 22, 32, 23, 77, 66, 29, 45, 40],
      "OPM %": ["14%", "14%", "17%", "23%", "26%", "19%", "21%", "15%", "30%", "21%", "10%", "14%", "11%"],
      "Other Income": [0, -1, 2, 0, 1, 3, 4, 1, 9, 13, 8, 16, 20],
      "Interest": [1, 2, 2, 2, 1, 2, 3, 3, 2, 2, 2, 2, 2],
      "Depreciation": [2, 2, 3, 3, 3, 5, 6, 7, 7, 8, 8, 8, 9],
      "Profit before tax": [4, 7, 13, 18, 23, 18, 28, 14, 76, 69, 27, 51, 50],
      "Tax %": ["35%", "32%", "35%", "36%", "35%", "29%", "27%", "26%", "27%", "24%", "24%", "24%", "24%"],
      "Net Profit": [3, 5, 8, 11, 15, 13, 20, 11, 55, 52, 20, 39, 38],
      "EPS in Rs": [4.71, 7.33, 13.48, 18.45, 24.10, 20.38, 32.58, 17.16, 89.79, 84.57, 32.57, 62.35, 60.89]
    }
  },
  "Ratios": {
    "Growth Ratios": {
      "Compounded Sales Growth": {
        "10 Years": "15%",
        "5 Years": "17%",
        "3 Years": "8%",
        "TTM": "23%"
      },
      "Compounded Profit Growth": {
        "10 Years": "23%",
        "5 Years": "14%",
        "3 Years": "-11%",
        "TTM": "13%"
      },
      "Stock Price CAGR": {
        "10 Years": "38%",
        "5 Years": "37%",
        "3 Years": "-7%",
        "1 Year": "4%"
      }
    },
    "Liquidity Ratios": {
      "Debtor Days": [100, 110, 107, 123, 110, 89, 79, 63, 53, 74, 86, 92],
      "Inventory Days": [126, 77, 106, 90, 114, 134, 106, 154, 132, 133, 69, 99],
      "Days Payable": [148, 105, 150, 122, 139, 187, 92, 114, 94, 84, 59, 110],
      "Cash Conversion Cycle": [78, 82, 63, 91, 85, 35, 93, 103, 91, 124, 97, 82],
      "Working Capital Days": [88, 88, 77, 96, 85, 54, 107, 98, 78, 116, 104, 106]
    },
    "Profitability Ratios": {
      "ROCE %": ["19%", "24%", "29%", "37%", "34%", "22%", "28%", "15%", "52%", "35%", "12%", "19%"],
      "ROE": {
        "10 Years": "22%",
        "5 Years": "21%",
        "3 Years": "17%",
        "Last Year": "16%"
      }
    },
    "Valuation Ratios": {
      "Price to Book": null, 
      "Market Cap / Sales": null,
      "EV / EBITDA": null
    }
  },
  "Peer Comparison": {
    "Peers": [
      {"Name": "Divi's Lab.", "CMP": 5846.75, "P/E": 84.54, "Mar Cap": 155212.84, "Div Yld": 0.51, "NP Qtr": 510.00, "Qtr Profit Var": 46.55, "Sales Qtr": 2338.00, "Qtr Sales Var": 22.47, "ROCE": 16.48},
      {"Name": "Neuland Labs.", "CMP": 13891.15, "P/E": 67.48, "Mar Cap": 17822.19, "Div Yld": 0.10, "NP Qtr": 32.84, "Qtr Profit Var": -63.20, "Sales Qtr": 310.84, "Qtr Sales Var": -25.59, "ROCE": 33.26},
      {"Name": "Jubilant Pharmo", "CMP": 1061.60, "P/E": 59.42, "Mar Cap": 16911.29, "Div Yld": 0.47, "NP Qtr": 102.50, "Qtr Profit Var": 81.29, "Sales Qtr": 1752.30, "Qtr Sales Var": 4.28, "ROCE": 6.74},
      {"Name": "Ami Organics", "CMP": 2120.40, "P/E": 92.93, "Mar Cap": 8679.74, "Div Yld": 0.14, "NP Qtr": 37.56, "Qtr Profit Var": 387.34, "Sales Qtr": 246.73, "Qtr Sales Var": 43.15, "ROCE": 15.99},
      {"Name": "Hikal", "CMP": 378.40, "P/E": 63.53, "Mar Cap": 4665.70, "Div Yld": 0.32, "NP Qtr": 18.30, "Qtr Profit Var": 45.58, "Sales Qtr": 452.90, "Qtr Sales Var": 4.14, "ROCE": 7.79},
      {"Name": "Aarti Drugs", "CMP": 428.25, "P/E": 31.48, "Mar Cap": 3937.12, "Div Yld": 0.23, "NP Qtr": 30.39, "Qtr Profit Var": -12.12, "Sales Qtr": 543.09, "Qtr Sales Var": -5.96, "ROCE": 13.68},
      {"Name": "Guj. Themis Bio.", "CMP": 307.85, "P/E": 63.64, "Mar Cap": 3354.50, "Div Yld": 0.22, "NP Qtr": 10.57, "Qtr Profit Var": -15.71, "Sales Qtr": 34.72, "Qtr Sales Var": -12.19, "ROCE": 44.99}
    ],
    "Median": {
      "CMP": 276.15,
      "P/E": 33.95,
      "Mar Cap": 409.76,
      "Div Yld": 0.12,
      "NP Qtr": 6.98,
      "Qtr Profit Var": 36.86,
      "Sales Qtr": 76.58,
      "Qtr Sales Var": 14.86,
      "ROCE": 13.88
    }
  },
  "Other Insights": {
    "Notes": [
      "Earnings include an other income of Rs.20.0 Cr.",
      "The pros and cons are machine generated.",
      "Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.",
      "The classifications might have changed from Sep'2022 onwards.",
      "The new XBRL format added more details from Sep'22 onwards.",
      "Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes."
    ]
  },
  "Shareholding Pattern": {
    "Quarterly": {
      "Promoters": [73.81, 73.81, 73.81, 73.81, 73.81, 73.53, 73.53, 73.06, 73.06, 72.74, 72.74, 72.74],
      "FIIs": [0.00, 0.01, 0.05, 0.05, 0.00, 0.00, 0.00, 0.02, 0.04, 0.10, 0.03, 0.02],
      "DIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.00, 0.01, 0.00, 0.00, 0.00, 0.00, 0.00],
      "Public": [26.19, 26.18, 26.14, 26.13, 26.19, 26.47, 26.46, 26.93, 26.91, 27.16, 27.24, 27.25]
    },
    "Yearly": {
      "Promoters": [73.85, 73.85, 73.85, 73.81, 73.81, 73.81, 73.53, 72.74, 72.74],
      "FIIs": [0.00, 0.00, 0.00, 0.00, 0.00, 0.01, 0.00, 0.10, 0.02],
      "Public": [26.15, 26.15, 26.15, 26.19, 26.19, 26.18, 26.47, 27.16, 27.25]
    },
    "No. of Shareholders": [15695, 17068, 18042, 18504, 18440, 18287, 17066, 17623, 16410, 15041, 14608, 14575, 4194, 4413, 4508, 4841, 5456, 17068, 18287, 15041, 14575]
  }
}
